C형 간염 치료제 시장 예측(-2030년) : 제품, 치료 유형, 약물 종류별, 투여 경로, 병기, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Hepatitis C Drugs Market is accounted for $25.92 billion in 2024 and is expected to reach $36.57 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Hepatitis C drugs are medications used to treat Hepatitis C, a viral infection that affects the liver. These drugs work by targeting the Hepatitis C virus (HCV) at various stages of its lifecycle, such as preventing viral replication or boosting the immune system's ability to fight the virus. These drugs are often used in combination, have significantly improved cure rates, reduced treatment durations, and minimized side effects.

According to the Centers for Disease Control and Prevention (CDC) in 2016, an estimated 3.5 million people in the United States suffered from chronic hepatitis C.

Market Dynamics:

Driver:

Increasing prevalence of hepatitis C

As more people are diagnosed with the infection, there is a growing need for advanced treatment options, particularly Direct-Acting Antivirals (DAAs), known for their high efficacy and minimal side effects. Public health initiatives and awareness campaigns further amplify screening and early detection efforts, creating a larger patient pool seeking treatment. Additionally, healthcare providers and governments focus on eradicating the disease, leading to investments in research, subsidies, and partnerships, which support market expansion and improved accessibility to Hepatitis C drugs.

Restraint:

Side effects and drug resistance

Side effects and drug resistance in Hepatitis C drugs stem from the variability in patient response and the virus's ability to mutate. Some treatments, particularly older regimens like interferon-based therapies, cause significant side effects, such as fatigue, depression, and flu-like symptoms, discouraging patient adherence. These factors hamper market growth by limiting treatment efficacy, increasing the need for alternative therapies, and reducing patient trust, ultimately slowing adoption and treatment completion rates.

Opportunity:

Expanding healthcare infrastructure and insurance coverage

Improved healthcare infrastructure increases access to diagnostic and treatment facilities, enabling earlier detection and timely intervention for Hepatitis C. Enhanced insurance coverage lowers the financial burden on patients, making expensive therapies like DAAs more affordable. Government initiatives and private sector investments in healthcare systems, particularly in emerging economies, further drive market growth by ensuring the availability of advanced treatments. These developments collectively encourage more patients to seek care, boosting demand for effective Hepatitis C drugs and improving overall health outcomes.

Threat:

Competition from generic drugs

Generics offer similar efficacy at a fraction of the cost, attracting price-sensitive patients and healthcare providers. This shift limits the market share of premium-priced branded drugs, especially in low- and middle-income regions. Additionally, the introduction of generics often leads to price wars, further compressing profit margins for companies. The availability of cost-effective generics also discourages investment in new drug development, potentially slowing innovation in the Hepatitis C treatment landscape.

Covid-19 Impact

The covid-19 pandemic significantly impacted the hepatitis C drugs market, disrupting healthcare systems, diagnostics, and treatments. The diversion of healthcare resources to manage covid led to delays in hepatitis C diagnosis and treatment initiation. Additionally, travel restrictions and lockdowns affected patient access to care and medications. However, increased awareness of public health and telemedicine helped sustain some treatment efforts. The pandemic also shifted focus toward enhancing healthcare infrastructure, which may aid in future Hepatitis C management post-covid.

The monotherapy segment is expected to be the largest during the forecast period

The monotherapy segment is predicted to secure the largest market share throughout the forecast period. Monotherapy in Hepatitis C treatment refers to using a single antiviral drug to treat the infection. Monotherapy involves interferon or ribavirin, but with the advent of Direct-Acting Antivirals (DAAs), monotherapy has become more effective and well-tolerated. It is often used for patients with specific genotypes or mild disease, minimizing side effects while ensuring effectiveness.

The chronic hepatitis C segment is expected to have the highest CAGR during the forecast period

The chronic hepatitis C segment is anticipated to witness the highest CAGR during the forecast period. Hepatitis C drugs used in chronic Hepatitis C treatment are primarily focused on eliminating the virus from the body and preventing liver damage. These drugs, often used in combination, are highly effective, offering high cure rates with minimal side effects. Treatment duration typically ranges from 8 to 12 weeks, and these therapies help reduce complications like cirrhosis, liver cancer, and liver failure.

Region with largest share:

Asia Pacific is expected to register the largest market share during the forecast period due to increasing awareness, improved healthcare access, and rising Hepatitis C prevalence. Countries like India, China, and Japan dominate the market, driven by large patient populations and government health initiatives. The region is also home for key players such as Bristol-Myers Squibb, Cipla, and Dr. Reddy's Laboratories. Rapid urbanization, expanding healthcare infrastructure, and favorable government policies are propelling the market's growth in this region.

Region with highest CAGR:

North America is expected to witness the highest CAGR over the forecast period driven by advanced healthcare systems and substantial investments in research and development. Key players in the region include Gilead Sciences, AbbVie Inc., Merck & Co., and Bristol-Myers Squibb. The region experiences steady market growth due to government-supported health programs, insurance coverage, and increasing efforts to eradicate Hepatitis C. The adoption of DAAs, coupled with initiatives targeting high-risk populations, ensures improved treatment access and outcomes, solidifying North America as a dominant market globally.

Key players in the market

Some of the key players profiled in the Hepatitis C Drugs Market include Gilead Sciences, AbbVie, Merck & Co., Johnson & Johnson, Bristol-Myers Squibb, Roche, GlaxoSmithKline, Eli Lilly and Company, Novartis, Sanofi, Pfizer, Boehringer Ingelheim, Mylan Pharmaceuticals, Teva Pharmaceuticals, Cipla, Hetero Drugs, NephroPlus, Aurobindo Pharma, Dr. Reddy's Laboratories and Zydus Cadila.

Key Developments:

In September 2024, NephroPlus has introduced a pioneering program aimed at addressing the critical issue of Hepatitis C in haemodialysis patients, particularly in regions with limited healthcare resources. This initiative highlights NephroPlus' ongoing commitment to enhancing patient care and reinforcing the health system's capabilities.

In April 2022, Bristol-Myers Squibb & Gilead Sciences entered a strategic collaboration to further develop their Hepatitis C drug pipelines. The deal focused on the combined development of new combination therapies for chronic Hepatitis C virus (HCV) infections, leveraging both companies' research assets to expand treatment options and improve cure rates.

Products Covered:

• Generic Hepatitis C Drugs
• Branded Hepatitis C Drugs

Treatment Types Covered:

• Combination Therapy
• Monotherapy

Drug Classes Covered:

• Direct-Acting Antivirals (DAAs)
• Protease Inhibitors
• NS5A Inhibitors
• NS5B Inhibitors
• Combination Drugs
• Ribavirin
• Other Drug Classes

Route Of Administrations Covered:

• Oral Drugs
• Injectable Drugs

Disease Stages Covered:

• Acute Hepatitis C
• Chronic Hepatitis C

End Users Covered:

• Hospitals
• Clinics
• Research & Diagnostic Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Hepatitis C Drugs Market, By Product

• 5.1 Introduction
• 5.2 Generic Hepatitis C Drugs
• 5.3 Branded Hepatitis C Drugs

6 Global Hepatitis C Drugs Market, By Treatment Type

• 6.1 Introduction
• 6.2 Combination Therapy
• 6.3 Monotherapy

7 Global Hepatitis C Drugs Market, By Drug Class

• 7.1 Introduction
• 7.2 Direct-Acting Antivirals (DAAs)
• 7.3 Protease Inhibitors
• 7.4 NS5A Inhibitors
• 7.5 NS5B Inhibitors
• 7.6 Combination Drugs
• 7.7 Ribavirin
• 7.8 Other Drug Classes

8 Global Hepatitis C Drugs Market, By Route Of Administration

• 8.1 Introduction
• 8.2 Oral Drugs
• 8.3 Injectable Drugs

9 Global Hepatitis C Drugs Market, By Disease Stage

• 9.1 Introduction
• 9.2 Acute Hepatitis C
• 9.3 Chronic Hepatitis C

10 Global Hepatitis C Drugs Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Clinics
• 10.4 Research & Diagnostic Laboratories
• 10.5 Other End Users

11 Global Hepatitis C Drugs Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Gilead Sciences
• 13.2 AbbVie
• 13.3 Merck & Co.
• 13.4 Johnson & Johnson
• 13.5 Bristol-Myers Squibb
• 13.6 Roche
• 13.7 GlaxoSmithKline
• 13.8 Eli Lilly and Company
• 13.9 Novartis
• 13.10 Sanofi
• 13.11 Pfizer
• 13.12 Boehringer Ingelheim
• 13.13 Mylan Pharmaceuticals
• 13.14 Teva Pharmaceuticals
• 13.15 Cipla
• 13.16 Hetero Drugs
• 13.17 NephroPlus
• 13.18 Aurobindo Pharma
• 13.19 Dr. Reddy's Laboratories
• 13.20 Zydus Cadila